サンプル依頼リスト カート
  • English
  • Korean
表紙：皮膚治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1297790

皮膚治療薬の世界市場-2023年～2030年

Global Dermatology Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
皮膚治療薬の世界市場-2023年～2030年
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

皮膚治療薬の世界市場規模は2022年に186億8,480万米ドルで、2030年には408億3,090万米ドルに達し、推定・予測期間（2023～2030年）のCAGRは10.5%で成長すると予測されています。

皮膚科学は、ニキビの克服、皮膚のシミの検査、皮膚がん検診、湿疹や乾癬の治療など、さまざまなことに役立つ。水面下で起こっていることに関しては、皮膚がすべてを教えてくれます。

市場力学

治療効果の高い医薬品の発売

顧客志向の新薬の頻繁なイントロダクションは、世界の皮膚治療薬事業に大きな影響を与えると予想されます。例えば、イーライリリーの乾癬治療薬がインドのDCGIから承認を取得し、インドの皮膚科市場への参入が可能になっています。ウェブサイトの開設、キャンペーン認知を促進するテレビやソーシャル・メディアのコマーシャルなどの新興国市場開拓手法も、予測期間中の市場発展を後押しすると思われます。

皮膚治療薬の価格上昇

皮膚治療薬に関連するコストの上昇が市場拡大の妨げとなっています。市場参入企業の多くは、回復を早めるために新薬の開発に多額の投資を行うが、そのためにコストが上昇します。その結果、すべての所得層にとって代替治療が現実的でないため、この問題は市場拡大の妨げとなっています。

COVID-19の影響分析

COVID-19は皮膚科の薬に恐ろしい影響を与えます。現在行われている皮膚治療薬の臨床試験の多くがパンデミックによって中断され、安全性への懸念、患者の診療所への受診制限、COVID-19研究のためのリソースの優先順位などの理由で多くの試験が中止または延期されたため、市場の成長に影響を及ぼしました。その結果、医薬品の研究と承認スケジュールは延期されました。

また、流行の結果、皮膚科クリニックへの患者の受診が減少し、選択手術が延期されました。その結果、皮膚科的問題の診断や治療が遅れた人もいたと思われます。この遅れは、疾病管理および全体的な結果に影響を及ぼす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 治療効果の高い医薬品の上市
    • 抑制要因
      • 皮膚治療薬の価格上昇
    • 機会
      • 高齢者人口の増加
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 薬剤クラス別

  • アトピー性皮膚炎
  • 乾癬
  • にきび
  • 脱毛症
  • ヘルペス
  • 酒さ

第8章 薬剤クラス別

  • 抗感染症薬
  • 抗ニキビ薬
  • カルシニューリン阻害薬
  • レチノイド
  • 副腎皮質ステロイド
  • その他の薬物クラス

第9章 エンドユーザー別

  • 病院
  • 皮膚科クリニック
  • 美容センター
  • その他

第10章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第11章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第12章 企業プロファイル

  • Leo Pharma
  • Allergan Inc.
  • Amgen Inc.
  • GI Dermatics
  • Sanofi
  • Merck & Co.
  • Pfizer
  • AbbVie
  • Bausch Health
  • Novartis

第13章 付録

目次
Product Code: PH1738

Market Overview

The Global Dermatology Drugs Market size was worth US$ 18,684.8 million in 2022 and is estimated to reach US$ 40,830.9 million by 2030, growing at a CAGR of 10.5% during the forecast period (2023-2030).

Dermatology can help people overcome acne, inspect skin blemishes, get skin cancer screenings, treat eczema and psoriasis, and much more. When it comes to things happening under the surface, your skin can tell you everything.

Market Dynamics

Launch of Therapeutically Effective Drugs

The frequent introduction of new and customer-focused goods is expected to have a greater impact on the global dermatological medicines business. For example, Eli Lilly's psoriasis treatment has received approval from India's DCGI, allowing the business to access the Indian dermatological market. Marketing methods such as website launches, TV and social media commercials promoting campaign awareness, and others will also aid in the market's development over the forecast period.

Rising Prices Of Dermatology Drugs

The increasing costs associated with these medications hinder market expansion. Many market participants make large investments in the development of new pharmaceuticals in order to speed up the recovery process, which raises the cost. As a result, this issue impedes market expansion because treatment alternatives are not practical for all income groups.

COVID-19 Impact Analysis

COVID-19 has a terrifying effect on dermatological medications. Many current clinical trials for dermatological treatments were interrupted by the pandemic, affecting market growth as many trials were discontinued or postponed due to safety concerns, limited patient visits to clinics, and prioritisation of resources for COVID-19 research. As a result, medication research and clearance schedules have been pushed back.

Also Patient visits to dermatological clinics were reduced as a result of the epidemic, and elective operations were postponed. As a result, some people may have had delayed diagnosis and treatment for dermatological problems. This delay may have an influence on illness management and overall results.

For more details on this report - Request For Sample

Segment Analysis

The global dermatology drugs market is segmented based on Application , Drug class and End user

The Acne Application Segment will be Dominated By Market Players During the Forecast Period.

Acne is expected to grow at a significant CAGR during the forecast period, owing to an increase in the number of market participants offering improved products internationally. Acne prevalence is also increasing, particularly among young people, which is a key factor contributing to the expansion of this category. Furthermore, the availability of a wide selection of acne products at retail pharmacies, as well as the convenience of access, are fueling the development of this market.

Geographical Analysis

North America is The Dominating Region During The Forecast Period.

Northa america has been dominating region for dermatology drugs market because of the rising incidence of dermatological infections. North America accounted for the majority of the market share of 38.7%. Another key aspect contributing to the region's growth is the presence of big businesses along with new launches. North America also possesses the most recent technology advances in R&D. This, together with increased dermatological product sales, is likely to fuel growth throughout the projection period. Furthermore, Asia Pacific is expected to have the highest CAGR due to increased public knowledge about the care and management of acne and other disorders.

Competitive Landscape

The major global players include: Leo Pharma, Allergan, Amgen Inc. GI Dermatics Sanofi Merck & Co. Pfizer, AbbVie, Bausch Health, and Novartis.

Why Purchase the Report?

  • To visualize the global dermatology drugs market segmentation based on the Application, drug class, end user and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global dermatology drugs market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global dermatology drugs market report would provide approximately 92 tables, 108 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Application
  • 3.2. Snippet by Drug class
  • 3.3. Snippet by End user

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Launch of therapeutically effective drugs
    • 4.1.2. Restraints
      • 4.1.2.1. Rising prices of dermatology drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Rise in elderly population
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Class

  • 7.1 Atopic Dermatitis
  • 7.2 Psoriasis
  • 7.3 Acne
  • 7.4 Alopecia
  • 7.5 Herpes
  • 7.6 Rosacea

8. By Drug Class

  • 8.1. Anti-Infectives
  • 8.2. Anti-Acne
  • 8.3. Calcineurin Inhibitors
  • 8.4. Retinoids
  • 8.5. Corticosteroids
  • 8.6. Other Drug classes

9. By End user

  • 9.1. Hospitals
  • 9.2. Dermatology Clinics
  • 9.3. Cosmetic Centers
  • 9.4 Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug class
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End user
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Leo Pharma
  • 12.2. Allergan Inc.
  • 12.3. Amgen Inc.
  • 12.4. GI Dermatics
  • 12.5. Sanofi
  • 12.6. Merck & Co.
  • 12.7. Pfizer
  • 12.8. AbbVie
  • 12.9. Bausch Health
  • 12.10. Novartis

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us